The Thromboembolism drugs in development market research report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thromboembolism. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thromboembolism and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Thromboembolism by 39 companies/universities/institutes. The top development phase for Thromboembolism is phase i with 16 drugs in that stage. The Thromboembolism pipeline has 41 drugs in development by companies and three by universities/ institutes. Some of the companies in the Thromboembolism pipeline products market are: Jiangsu Hengrui Medicine, Suzhou Ribo Life Sciences and Taho Pharmaceuticals.

The key targets in the Thromboembolism pipeline products market include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6), Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27), and Plasminogen (Plasmin or PLG or EC 3.4.21.7).

The key mechanisms of action in the Thromboembolism pipeline product include Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6) Inhibitor with 11 drugs in Filing rejected/Withdrawn. The Thromboembolism pipeline products include ten routes of administration with the top ROA being Oral and ten key molecule types in the Thromboembolism pipeline products market including Small Molecule, and Monoclonal Antibody.

Thromboembolism overview

A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery.

For a complete picture of Thromboembolism’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.